Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile
suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.